desmethyltrimipramine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

desmethyltrimipramine: major metabolite of trimipramine; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	160632
MeSH ID	M0120848

Synonyms (26)

Synonym
nortrimipramine
FT-0665751
2293-21-2
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n,2-dimethylpropan-1-amine
desmethyltrimipramine
unii-i453qu04o6
i453qu04o6 ,
5h-dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-n,beta-dimethyl-
n-demethyl trimipramine
n-desmethyltrimipramine
monodemethyltrimiprimine
monodesmethyltrimipramine
trimipramine maleate impurity b [ep impurity]
5h-dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-n,.beta.-dimethyl-
n-desmethyltrimipramine, (rs)-
trimipramine maleate impurity, desmethyltrimipramine- [usp impurity]
FUEUKSCRQNPXKS-UHFFFAOYSA-N
3-(10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)-n,2-dimethyl-1-propanamine #
BS-47086
Q27280397
3-(10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)-n,2-dimethylpropan-1-amine
DTXSID70945611
STARBLD0004854
n-desmethyltrimipramine,1.0mg/mlinmethanol
F74295
AKOS040759682

Research Excerpts

Pharmacokinetics

Excerpt	Reference	Relevance
" The mean plasma half-life and AUC of amitriptyline oxide and its metabolites were significantly higher in patients than in healthy adults."	( [Comparative study of the pharmacokinetics of amitriptyline oxide and trimipramine after single administration in healthy male probands and patients with renal failure]. Degen, J; Fischer, W; Höxter, G; Pintar, P; Seiberling, M; Steinhauer, HB; Wölke, E, 1993)	0.29

Bioavailability

Excerpt	Reference	Relevance
" Absolute bioavailability was 41."	( Trimipramine kinetics and absolute bioavailability: use of gas-liquid chromatography with nitrogen-phosphorus detection. Abernethy, DR; Greenblatt, DJ; Shader, RI, 1984)	0.27
" However, the effect of CYP2D6 genotype on steady state kinetics and on bioavailability has not been studied so far."	( Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity. Brockmöller, J; Kirchheiner, J; Meineke, I; Roots, I; Sasse, J, 2003)	0.32
"Both bioavailability and systemic clearance significantly depended on CYP2D6 genotype with a linear gene dose relationship."	( Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity. Brockmöller, J; Kirchheiner, J; Meineke, I; Roots, I; Sasse, J, 2003)	0.32
"High bioavailability combined with low systemic clearance of trimipramine in poor metabolizers of CYP2D6 substrates results in a very high exposure to trimipramine with the risk of adverse drug reactions."	( Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity. Brockmöller, J; Kirchheiner, J; Meineke, I; Roots, I; Sasse, J, 2003)	0.32

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	3 (30.00)	18.7374
1990's	6 (60.00)	18.2507
2000's	1 (10.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.82 (24.57)
Research Supply Index	2.56 (2.92)
Research Growth Index	4.39 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.82)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (9.09%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	2 (18.18%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (72.73%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
amitriptyline Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.. amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.	3.37	1	1	carbotricyclic compound; tertiary amine	adrenergic uptake inhibitor; antidepressant; environmental contaminant; tropomyosin-related kinase B receptor agonist; xenobiotic
citalopram Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.. citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.. 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.	2	1	0	2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound
clomipramine Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.. clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.	1.96	1	0	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor
nortriptyline Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.. nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.	3.37	1	1	organic tricyclic compound; secondary amine	adrenergic uptake inhibitor; analgesic; antidepressant; antineoplastic agent; apoptosis inducer; drug metabolite
trimipramine Trimipramine: Tricyclic antidepressant similar to IMIPRAMINE, but with more antihistaminic and sedative properties.. trimipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)-2-methylpropyl group at the nitrogen atom. It is used as an antidepressant.	10.07	10	1	dibenzoazepine; tertiary amino compound	antidepressant; environmental contaminant; xenobiotic
zolpidem Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.. zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.	2	1	0	imidazopyridine	central nervous system depressant; GABA agonist; sedative
amitriptyline n-oxide [no description available]	3.37	1	1	organic tricyclic compound
2-hydroxytrimipramine 2-hydroxytrimipramine: metabolite of trimipramine; structure given in first source	2.9	4	0
monodesmethylcitalopram monodesmethylcitalopram: metabolite of citalopram	2	1	0	benzenes; organic amino compound

Condition	Relationship Strength	Studies	Trials
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	1.98	1	0
Chronic Kidney Failure [description not available]	3.37	1	1
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	3.37	1	1
Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.	2	1	0
Drug Overdose Accidental or deliberate use of a medication or street drug in excess of normal dosage.	2	1	0

chemdatabank.com